Tags

Type your tag names separated by a space and hit enter

Cilostazol and diltiazem attenuate cyclosporine-induced nephrotoxicity in rats.
Transplant Proc. 2012 Jul-Aug; 44(6):1738-42.TP

Abstract

AIM

Cyclosporine (CsA), an important agent used in organ transplantation to prevent rejection, displays nephrotoxicity as the most important side effect limiting usage. In this study, we sought to evaluate the effects of cilostazol and diltiazem to counter the nephrotoxicity induced by the calcineurin inhibitor CsA.

MATERIALS AND METHODS

Animals were randomly divided into seven groups, each consisting of eight animals: sham, controls, cilostazol, diltiazem, CsA, CsA plus diltiazem, and CsA plus cilostazol treatment. At the end of a 60-minute ischemic period, we administered the drugs after reperfusion for 7 days thereafter. CsA (10 mg/kg/d) was intraperitoneally for 7 days; cilostazol (10 mg/kg/d) orally by catheter for 7 days; diltiazem (5 mg/kg/d) intraperitoneally for 7 days. At the end of the 7-day treatment period, blood and tissue samples were harvested for biochemical, and serological evaluation.

RESULTS

Ischemia-reperfusion injury significantly increased malondialdehyde (MDA) levels as well as decreased catalase (CAT) activities and superoxide dysmutase (SOD) content. The lowest MDA mean level was observed in the diltiazem and, the highest in the control group. The lowest CAT mean levels were noted in the CsA and diltiazem groups with highest CAT content was in the CsA and cilostazol groups. The lowest SOD mean level occurred in the sham group; the highest, in the CsA group.

CONCLUSION

Cilostazol and especially diltiazem were effective to mitigate renal ischemia-reperfusion injury.

Authors+Show Affiliations

Department of General Surgery and Renal Transplantation Center, School of Medicine, Kahramanmaras Sutcuimam University, Kahramanmaras, Turkey.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22841259

Citation

Gokce, M, et al. "Cilostazol and Diltiazem Attenuate Cyclosporine-induced Nephrotoxicity in Rats." Transplantation Proceedings, vol. 44, no. 6, 2012, pp. 1738-42.
Gokce M, Yuzbasioglu MF, Bulbuloglu E, et al. Cilostazol and diltiazem attenuate cyclosporine-induced nephrotoxicity in rats. Transplant Proc. 2012;44(6):1738-42.
Gokce, M., Yuzbasioglu, M. F., Bulbuloglu, E., Oksuz, H., Yormaz, S., Altınoren, O., Kutlucan, M., Coskuner, I., Silay, E., & Kale, I. T. (2012). Cilostazol and diltiazem attenuate cyclosporine-induced nephrotoxicity in rats. Transplantation Proceedings, 44(6), 1738-42. https://doi.org/10.1016/j.transproceed.2012.04.025
Gokce M, et al. Cilostazol and Diltiazem Attenuate Cyclosporine-induced Nephrotoxicity in Rats. Transplant Proc. 2012 Jul-Aug;44(6):1738-42. PubMed PMID: 22841259.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cilostazol and diltiazem attenuate cyclosporine-induced nephrotoxicity in rats. AU - Gokce,M, AU - Yuzbasioglu,M F, AU - Bulbuloglu,E, AU - Oksuz,H, AU - Yormaz,S, AU - Altınoren,O, AU - Kutlucan,M, AU - Coskuner,I, AU - Silay,E, AU - Kale,I T, PY - 2012/7/31/entrez PY - 2012/7/31/pubmed PY - 2013/1/4/medline SP - 1738 EP - 42 JF - Transplantation proceedings JO - Transplant Proc VL - 44 IS - 6 N2 - AIM: Cyclosporine (CsA), an important agent used in organ transplantation to prevent rejection, displays nephrotoxicity as the most important side effect limiting usage. In this study, we sought to evaluate the effects of cilostazol and diltiazem to counter the nephrotoxicity induced by the calcineurin inhibitor CsA. MATERIALS AND METHODS: Animals were randomly divided into seven groups, each consisting of eight animals: sham, controls, cilostazol, diltiazem, CsA, CsA plus diltiazem, and CsA plus cilostazol treatment. At the end of a 60-minute ischemic period, we administered the drugs after reperfusion for 7 days thereafter. CsA (10 mg/kg/d) was intraperitoneally for 7 days; cilostazol (10 mg/kg/d) orally by catheter for 7 days; diltiazem (5 mg/kg/d) intraperitoneally for 7 days. At the end of the 7-day treatment period, blood and tissue samples were harvested for biochemical, and serological evaluation. RESULTS: Ischemia-reperfusion injury significantly increased malondialdehyde (MDA) levels as well as decreased catalase (CAT) activities and superoxide dysmutase (SOD) content. The lowest MDA mean level was observed in the diltiazem and, the highest in the control group. The lowest CAT mean levels were noted in the CsA and diltiazem groups with highest CAT content was in the CsA and cilostazol groups. The lowest SOD mean level occurred in the sham group; the highest, in the CsA group. CONCLUSION: Cilostazol and especially diltiazem were effective to mitigate renal ischemia-reperfusion injury. SN - 1873-2623 UR - https://www.unboundmedicine.com/medline/citation/22841259/Cilostazol_and_diltiazem_attenuate_cyclosporine_induced_nephrotoxicity_in_rats_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0041-1345(12)00421-6 DB - PRIME DP - Unbound Medicine ER -